Skip to main content
SpringerLink
Log in

FDA warns against off-label use of ketoconazole oral tablets

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • US Food and Drug Administration. FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death. Internet Document : 19 May 2016. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm500597.htm

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

FDA warns against off-label use of ketoconazole oral tablets. Reactions Weekly 1604, 3 (2016). https://doi.org/10.1007/s40278-016-18059-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-18059-9

Search

Navigation